IOVANCE BIOTHERAPEUTICS, INC. (IOVA) FY2026 YTD Q2 P&L / Income Statement

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenue

170,743,000 US dollars

Cost of sales

86,093,000 US dollars

Gross profit (calculated)

84,650,000 US dollars

Operating expenses (calculated)

217,598,000 US dollars

Loss from operations

negative 132,948,000 US dollars

Other income (expense), net (calculated)

4,550,000 US dollars

Net Loss before income taxes

negative 128,398,000 US dollars

Income tax benefit (expense)

negative 2,038,000 US dollars

Net Loss

negative 126,360,000 US dollars

Amtagvi

150,943,000 US dollars

Proleukin

19,800,000 US dollars

Research and development

121,338,000 US dollars

Selling, general, and administrative

78,221,000 US dollars

Depreciation and amortization

18,039,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.